Showing results (181-190 of 19,456) with videos related to

Sort By:
Pageof 1,946
Lancet (London, England)|November 1, 2025
Biomedical innovations in contraception: gaps, obstacles, and solutions for sexual and reproductive healthDeborah J Anderson, Jonathan M Bearak, Frances W Grimstad, et al.
Lancet (London, England)|November 1, 2025
Who pays and what pays off in sexual and reproductive health? A review of the cost and cost-effectiveness of interventions and implications for future funding and marketsGesine Meyer-Rath, Lise Jamieson, Edinah Mudimu, et al.
Lancet (London, England)|November 1, 2025
Challenges and opportunities in developing integrated sexual and reproductive health programmesKenneth H Mayer, Chris Beyrer, Myron S Cohen, et al.
Lancet (London, England)|March 15, 2025
Behavioural interventions to increase uptake of FIT colorectal screening in Scotland (TEMPO): a nationwide, eight-arm, factorial, randomised controlled trialKathryn A Robb, Ben Young, Marie K Murphy, et al.
Lancet (London, England)|September 25, 2023
CAR T-cell therapy in autoimmune diseasesGeorg Schett, Andreas Mackensen, Dimitrios Mougiakakos
Lancet (London, England)|September 22, 2023
Primary brain tumours in adultsMartin J van den Bent, Marjolein Geurts, Pim J French, et al.
Lancet (London, England)|September 22, 2023
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trialAkimichi Morita, Bruce Strober, A David Burden, et al.
Lancet (London, England)|September 23, 2023
Hepatitis CMarianne Martinello, Sunil S Solomon, Norah A Terrault, et al.
Lancet (London, England)|January 28, 2025
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trialThierry André, Elena Elez, Heinz-Josef Lenz, et al.
Lancet (London, England)|March 5, 2021
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trialMelanie Davies, Louise Færch, Ole K Jeppesen, et al.
Pageof 1,946